Cargando…

ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma

Over the last few years, a significant progress has been made in understanding the role of a disintegrin and metalloproteinase 33 (ADAM33) in asthma. The previous observations for the association with asthma have been replicated in over 33 different population samples worldwide. We and others have p...

Descripción completa

Detalles Bibliográficos
Autores principales: Tripathi, Priya, Awasthi, Shally, Gao, Peisong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003756/
https://www.ncbi.nlm.nih.gov/pubmed/24817794
http://dx.doi.org/10.1155/2014/572025
_version_ 1782313879616880640
author Tripathi, Priya
Awasthi, Shally
Gao, Peisong
author_facet Tripathi, Priya
Awasthi, Shally
Gao, Peisong
author_sort Tripathi, Priya
collection PubMed
description Over the last few years, a significant progress has been made in understanding the role of a disintegrin and metalloproteinase 33 (ADAM33) in asthma. The previous observations for the association with asthma have been replicated in over 33 different population samples worldwide. We and others have performed association analysis and meta-analysis and provided further evidence that several polymorphisms in the ADAM33 are risk factors for asthma, especially in the Asian population. Further, several studies have suggested that alterations in epigenetic marks alter the patterns of DNA methylation of ADAM33 and result in potentially adverse biological effects. Finally, while the biological activities of ADAM33 are as yet unknown, ADAM33 may play a possible role in airway remodeling because of its high expression in epithelium, myo/fibroblasts, and airway smooth muscle cells (ASMCs) and its role in promoting angiogenesis and stimulating cell proliferation and differentiation. Thus, ADAM33 represents a promising target for asthma. However, further investigations are clearly needed to discover functional ADAM33 gene polymorphisms and the role of genetic/epigenetic factors in conferring genetic susceptibility to environmental exposure induced asthma as well as biological function in asthma. This, in turn, will unlock the possibility of ADAM33 as a target for asthma therapy.
format Online
Article
Text
id pubmed-4003756
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40037562014-05-11 ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma Tripathi, Priya Awasthi, Shally Gao, Peisong Mediators Inflamm Review Article Over the last few years, a significant progress has been made in understanding the role of a disintegrin and metalloproteinase 33 (ADAM33) in asthma. The previous observations for the association with asthma have been replicated in over 33 different population samples worldwide. We and others have performed association analysis and meta-analysis and provided further evidence that several polymorphisms in the ADAM33 are risk factors for asthma, especially in the Asian population. Further, several studies have suggested that alterations in epigenetic marks alter the patterns of DNA methylation of ADAM33 and result in potentially adverse biological effects. Finally, while the biological activities of ADAM33 are as yet unknown, ADAM33 may play a possible role in airway remodeling because of its high expression in epithelium, myo/fibroblasts, and airway smooth muscle cells (ASMCs) and its role in promoting angiogenesis and stimulating cell proliferation and differentiation. Thus, ADAM33 represents a promising target for asthma. However, further investigations are clearly needed to discover functional ADAM33 gene polymorphisms and the role of genetic/epigenetic factors in conferring genetic susceptibility to environmental exposure induced asthma as well as biological function in asthma. This, in turn, will unlock the possibility of ADAM33 as a target for asthma therapy. Hindawi Publishing Corporation 2014 2014-04-10 /pmc/articles/PMC4003756/ /pubmed/24817794 http://dx.doi.org/10.1155/2014/572025 Text en Copyright © 2014 Priya Tripathi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Tripathi, Priya
Awasthi, Shally
Gao, Peisong
ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma
title ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma
title_full ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma
title_fullStr ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma
title_full_unstemmed ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma
title_short ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma
title_sort adam metallopeptidase domain 33 (adam33): a promising target for asthma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003756/
https://www.ncbi.nlm.nih.gov/pubmed/24817794
http://dx.doi.org/10.1155/2014/572025
work_keys_str_mv AT tripathipriya adammetallopeptidasedomain33adam33apromisingtargetforasthma
AT awasthishally adammetallopeptidasedomain33adam33apromisingtargetforasthma
AT gaopeisong adammetallopeptidasedomain33adam33apromisingtargetforasthma